Novel First-in-Class Drugs

Cleave Biosciences has a pipeline of novel, first-in-class therapeutics targeting protein degradation pathways for difficult to treat cancers as well as a deep understanding of the biology of these pathways. Our lead drug candidate CB-5083 began clinical trials in patients with Multiple Myeloma and Advanced Solid Tumors. Other Cleave programs focused on AAA ATPases and novel zinc-dependent JAMM metalloproteases are at the discovery stage.

Inquiries related to potential partnering opportunities can be directed to info@cleavebio.com.